S
oft tissue sarcomas comprise a rare and heterogeneous group of cancers, with approximately 13,040 new cases per year and more than 50 different histologic subtypes. 1 Of these, only 10-15% arise in the retroperitoneum, which makes study of retroperitoneal sarcoma (RPS) and the development of a meaningful staging system difficult. Since 1977 the American Joint Committee on Cancer (AJCC) has used available evidence-based literature to construct staging systems for many cancers. In addition to the three variables that comprise the foundation of most cancer staging systems-tumor size (T), nodal status (N), and distant metastases (M)-sarcoma staging has included grade (G) and tumor depth (superficial/deep) since its inception in 1992. 2 Yet even with the incorporation of these additional variables, previous staging systems for sarcoma have been found lacking, and their application to RPS in particular has been questioned. [3] [4] [5] [6] [7] Previous staging criteria were based largely on data that included a majority of patients with extremity or trunk sarcomas, which have a tumor biology distinct from RPS. 8, 9 Additionally, the T and N categories may be less meaningful for RPS, as nodal disease is prognostic but rare 3, 10 and tumor size at the time of diagnosis is often larger than historical staging parameters. 4, 6, [10] [11] [12] [13] [14] [15] The recently released AJCC eighth edition staging manual addresses some of these concerns. The eighth edition creates a separate staging system specific to the retroperitoneal location, appropriately removes the superficial/deep category formerly used for tumors in nonretroperitoneal locations, and adds 2 additional T categories to characterize larger tumors. 16 The previous T1 category is preserved ( ≤ 5 cm), tumors that are > 5 cm but ≤ 10 cm are now T2, tumors that are > 10 cm but ≤ 15 cm are now T3, and tumors that are > 15 cm are T4. These changes result in reclassification of patients from the IIB/III groups in the seventh edition to the IIIA/IIIB groups in the eighth edition (Figs. 1A-C) . The value of the updated AJCC staging classification is unclear.
Recently an analysis using the Surveillance, Epidemiology, and End Results (SEER) database found the predictive accuracy and concordance indices of the AJCC eighth edition staging system to be lower than the previous version, with tumor size having only a limited effect on overall survival (OS) after accounting for other prognostic factors. 17 In contrast to SEER, which is population based, the National Cancer Database (NCDB) collects hospital-based registry data specifically from Commission on Cancer accredited facilities, thus representing an assessment of practice patterns amongst institutions with a specific focus on cancer medicine. 18, 19 In the current study, we use the NCDB to evaluate the prognostic value of the AJCC eighth edition staging system for RPS.
MATERIALS AND METHODS
The NCDB Participant User File for sarcoma was queried for patients age 18 years or older with retroperitoneal tumors treated at the reporting facility between January 1, 1998 and December 31, 2011, using the International Classification of Disease for Oncology (third ed) topography code C480. The histologic subtypes were reviewed, and the following histologic subtypes were excluded: nonsarcomatous or mixed histologies and dermatofibrosarcoma protuberans. Patients with <90 days of follow-up, significant gaps in their clinical data, and/or inadequate information for tumor, node, and metastasis (TNM) staging for classification according to the AJCC seventh or eighth edition staging systems were also excluded. Patients with stage T0, tumor size recorded as "0," or discordant classification between pathologic node status and number of nodes assessed (ie, pathologic node positive and number of nodes assessed = 0) were excluded. Patients with localized disease who did not undergo surgery were excluded (Supplemental Kaplan-Meier survival curves and Cox proportional hazard models were used to evaluate OS. Univariate and multivariate analyses were performed to identify factors associated with OS. Concordance indices (C-index) were calculated to evaluate the discriminatory power of the seventh and eighth AJCC staging editions. Analyses were performed using SAS 9.4 (Cary, NC), with statistical significance defined at P < 0.05. Table 1 demonstrates the demographics and clinical characteristics of the 6427 patients with retroperitoneal sarcoma in the study. Liposarcoma was the most common histology (n = 3304, 51.4%), followed by leiomyosarcoma (n = 1892, 29.4%), and sarcoma not otherwise specified (NOS, n = 354, 5.5%).
RESULTS

Patient Characteristics
The median tumor size was 15 cm (range, 3 to 99 cm) with 9% of patients having tumors ≤ 5 cm (n = 580), 19.4% with tumors 5 < x ≤ 10 cm (n = 1246), 20.2% with tumors 10 < x ≤ 15 cm (n = 1298) and 47.4% with tumors > 15 cm (n = 3045).
Most patients were treated with surgical resection (radical resection n = 3082, 48.0%; local resection n = 2181, 33.9%; debulking n = 309, 4.8%; unknown surgical resection n = 265, 4.1%). A small subset of patients received chemotherapy (n = 1146, 17.8%) and/or radiation therapy (n = 1769, 27.5%). The majority of patients underwent an R0/R1 resection (n = 3956, 61.4%); data on concomitant organ resection were not available. As expected, surgical lymph node assessment was uncommon, with 21.3% (n = 1372) undergoing pathologic assessment of at least one node. 
Staging
Overall Survival
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Role of T stage
In the seventh edition, patients with T1 and T2 disease had a 5-year OS of 57.5% and 52.4%, respectively (P < 0.001). In the eighth edition, 5-year OS based on T stage alone was 57.5%, 55.1%, 51.8%, and 51.5% for T1, T2, T3, and T4 patients, respectively, P = 0.007 (Figs. 2C, D) .
When analyzed as a continuous variable amongst patients with stage I-III disease, increasing tumor size was significantly associated with decreased OS, although the HR for each centimeter increase was small (HR = 1.004; 95% CI: 1.000-1.007; P = 0.04). When dichotomized at 5 cm intervals for tumors up to 25 cm, a significant effect on OS for each size group was identified starting with tumors > 10 cm (Supplemental Table 1 , Supplemental Digital content 2, http://links.lww.com/AJCO/ A227).
Univariate and Multivariate Analyses
Amongst patients with localized disease (stages I-III), univariate analysis identified older age, male sex, government insurance status, treatment at a nonacademic facility, debulking resection, incomplete surgical resection, higher T stage, higher grade, presence of nodal disease, chemotherapy administration, and lack of radiation therapy were factors associated with poorer OS. In a multivariate model which included only patients with complete information (n = 3,681), T stage remained a weak prognostic factor for OS with a significant difference noted between patients with T4 versus T1 tumors (HR 1.3; 95% CI 1.08-1.57; P < 0.001, Table 3 ). A significant association with OS was not observed for patients with T2 or T3 tumors as compared with T1 tumors. High tumor grade, incomplete (R2) resection and debulking procedures were associated with the highest HRs for death (Table 3) .
For patients with metastatic disease (n = 749) increasing age, male sex, government insurance status, treatment at a nonacademic facility, and high-grade tumors were associated with poorer OS, whereas selection for surgery was associated with better OS (Supplemental Table 2 , Supplemental Digital Content 3, http://links.lww.com/AJCO/A228).
DISCUSSION
The current study uses the NCDB to evaluate the performance of the eighth edition AJCC staging manual for RPS. Our results suggest that while adding additional T stage categories may more accurately characterize tumor size, the overall outcome with respect to the prognostication for OS among these subgroups is minimal. Other clinicopathologic factors such as tumor grade and ability to achieve a complete surgical resection are associated with greater differences in patient survival compared with tumor size.
Historically, knowledge regarding the prognostic factors and outcomes for patients with RPS was based on retrospective analyses from single, high-volume institutions. 4, 11, [20] [21] [22] More recently, researchers have utilized regional 23 or national databases, 6, 10, [24] [25] [26] [27] [28] or formed multi-institutional working groups, 15, 29 with some spanning multiple countries, 14 to define factors that influence outcomes of patients with RPS. The results with respect to the role of tumor size as a prognostic factor are conflicting. In one of the largest single institution series (n = 500), tumor size > 10 cm was associated with decreased OS on multivariate analysis in patients with primary RPS (HR = 1.7; 95% CI: 1.1-2.7; P = 0.02) but was not associated with distant metastasis free survival or locoregional recurrence. 20 Others have supported using 10 cm as a prognostic cutpoint, 10 or shown a similar relationship between OS and tumor size using 15 cm as a cutpoint. 4, 25, 30 Many investigators, however, have not found a relationship between tumor size and outcome at all. 13, 15, 20, [31] [32] [33] In a Surveillance, Epidemiology, and End Results (SEER) analysis spanning 17 years and including 1,365 patients, Nathan et al 6 was unable to identify an association between tumor size and OS when using tumor size either as a continuous variable or dichotomized at various cutpoints, including 20 cm, 10 cm, as well as the AJCC seventh edition cutpoint of 5 cm. Similarly, Berger et al 26 *Percent total refers to the total within the respective seventh or eighth edition staging system, with 4.0% unknown in both. † Includes pathologic node positive (n = 141) and clinically node positive (n = 81).
Ed. indicates edition; NOS, not otherwise specified; R0, negative microscopic margins; R1, microscopic positive margin; R2, gross positive margin.
having a greater impact on OS, which are well accepted within the literature as negative prognostic factors. 10, 12, 20, 21, 27, 33, 34 One potential explanation for the conflicting data pertaining to tumor size as a prognostic factor is the possibility that the effect is bimodal-that is, tumor size may be prognostic up to a certain point, but after that larger tumors may demonstrate indolent biology and behavior. In an analysis of 192 patients, Ardoino et al 11 found that the relative hazard for death after resection of primary nonmetastatic RPS increased with tumor size up to 25 cm, and decreased thereafter, similar to the findings in the current study. This relationship is also captured in 2 RPS specific nomograms, in which increasing tumor size is associated with a worse prognosis up to 30 cm, and then reverses for tumors larger than 30 cm. 7, 35 The current AJCC eighth edition staging system is not structured to capture this relationship. Although one advantage of an NCDB study is that it represents practice patterns across multiple institutions with cancer-specific standards, the large registry-based nature also results in inevitable heterogeneity of data despite rigorous quality controls. The rarity of RPS, presence of multiple histologic subtypes and grading schema, changes in usage of diagnostic terms over time, and impracticality of central pathologic review when using a large registry further contribute to variability and risk of diagnostic error. 36 Therefore, the current work is limited in its ability to evaluate prognosis based on specific histologic subtype. Large volume single institution or multiple institution studies with central pathologic review are better suited to evaluate the role of histology on prognosis, and have been used to develop sarcoma specific nomograms incorporating the histologic subtype. 4, 7, 11, 35 In the eighth edition, the AJCC recognized the need for more personalized prognostic tools across all disease sites and encouraged the use of well validated nomograms. Of the four currently available nomograms specific to RPS, 4, 7, 11, 35 the AJCC endorsed a model designed by Gronchi et al 7 for patients with RPS undergoing curative intent resection and externally validated in 2 separate studies. 37, 38 The model incorporates tumor size and grade, and also takes into account factors not captured by the AJCC staging manual: 7 histologic categories, patient age, multifocality, and extent of resection. Nomograms are exceedingly useful tools for calculating individual patient risk but cannot replace the need for a common language that can accurately and efficiently describe and compare groups of patients.
CONCLUSIONS
The creation of a specific staging system for retroperitoneal sarcoma and the addition of larger T stages is a move towards more accurate description, but the discriminatory power of the AJCC eighth edition staging manual for retroperitoneal sarcoma remains limited. Future staging modifications within the confines of the TNMG system should consider larger T size categories and account for the possibility of a bimodal effect of tumor size on survival. 
